Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
20 February, 2018 13:11 IST
Lupin receives USFDA nod for generic Seroquel XR tablets
Source: IRIS | 19 May, 2017, 08.20AM
Comments  |  Post Comment

Pharma Major Lupin announced today that it has received final approval for its Quetiapine Fumarate Extended-Release Tablets, 50 mg, 150 mg, 200 mg, 300 mg and 400 mg from the United States Food and Drug Administration (FDA) to market a generic version of AstraZeneca Pharmaceuticals LP's Seroquel XR Tablets 50 mg, 150 mg, 200 mg, 300 mg and 400 mg.

Lupin's Quetiapine Fumarate Extended-Release Tablets, 50 mg, 150 mg, 200 mg, 300 mg and 400 mg are the AB rated generic equivalent of AstraZeneca Pharmaceuticals LP's Seroquel XR Tablets 50 mg, 150 mg, 200 mg, 300 mg and 400 mg.

It is indicated for the treatment of schizophrenia; acute manic or mixed episodes in bipolar I disorder alone or as an adjunct to lithium or divalproex; acute depressive episodes in bipolar disorder; maintenance treatment of bipolar I disorder, as an adjunct to lithium or divalproex and as an adjunctive therapy to antidepressants for the treatment of major depressive disorder.

Seroquel XR Extended-Release Tablets had US sales of USD 1.27 billion (IMS MAT March 2017).

Shares of the company gained Rs 7.85, or 0.61%, to trade at  Rs 1,304.90.  The total volume of shares traded  was  67,273 at the BSE (4.01 p.m., Thursday).



Lupin Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Related Articles
Suven Life Sciences secures product patents in India and South Korea - 20-Feb-2018 10:47
IndusInd Bank intimates of no direct credit exposure to Nirav Modi - 20-Feb-2018 09:58
JSW Energy enters into MoU with Govt of Maharashtra - 20-Feb-2018 09:53
Subex partners with Pod Solution - 20-Feb-2018 09:49
Glenmark Pharma presents findings from Phase 2a study of GBR 830 - 19-Feb-2018 10:10
L&T Construction secures order worth Rs 16.80 bn - 19-Feb-2018 09:52
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer